Emerging role of antileukotriene therapy in allergic rhinitis

Clinical and Experimental Allergy

Volumn 31, Issue 12, 2001, Pages 1813-1821

  Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BECLOMETASONE; BUDESONIDE; CHLORPHENIRAMINE; CORTICOSTEROID; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LORATADINE; MEQUITAZINE; MONTELUKAST; PRANLUKAST; VERLUKAST; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HISTAMINE ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; NASAL POLYPS; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0035663121     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01202.x     Document Type: Review

References (49)

1. Leukotriene-receptor antagonists
2. Allergic inflammation in the unified airway: Start with the nose
3. The role of leukotrienes in allergic rhinitis: A review
4. Pharmacology of leukotriene receptor antagonists
5. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor
6. 1 receptor
7. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription
8. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
9. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast
10. Mediator release after nasal airway challenge with allergen
11. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed
12. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge
13. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis
14. Nasal physiology and inflammatory mediators during natural pollen exposure
15. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
16. The role of leukotriene D4 in allergic rhinitis
17. The effect of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast) on agonist and antigen induced nasal microvascular leakage in guinea pigs
18. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor
19. The influence of 5-lipoxygenase inhibition in allergic rhinitis
20. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy
21. 4-receptor blockade of mast cell medicated contraction in sensitised human bronchus
22. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
23. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast
24. Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis
25. The leukotriene D4-receptor antagonist, ICI 204, 219, relieves symptoms of acute seasonal allergic rhinitis
26. Pranlukast (ultair, SB205312, ONO1078), an oral leukotriene receptor antagonist relive symtpoms in patients with seasonal allergic rhinitis
27. Montelukast in the treatment of spring allergic rhinitis in a large double blind randomised placebo controlled study
28. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis
29. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
30. Effects of a leukotriene receptor antagonist, pranlukast hydrate, on airway inflammation and airway hyperresponsiveness in patients with moderate to severe asthma
31. Effect of pranlukast on bronchial inflammation in patients with asthma
32. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma
33. Combination therapy with anti-mediator drugs in allergic disease
34. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow
35. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
36. Treatment of fall allergic rhinitis with Montelukast alone or in combination with loratadine in a multicenter double blind randomised placebo controlled study
37. Improvement in rhinoconjunctivitis quality of life outcomes in the treatment of fall allergic rhinitis by Montelukast alone or in combination with loratadine in a multicenter double blind randomised placebo controlled study
38. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis
39. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis
40. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit
41. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis
42. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis
43. Antiasthmatic effect mediator blockade versus topical corti-costeroids in allergic rhinitis and asthma
44. Effects of topical corticosteroid and combined medicator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis
45. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma
46. 4 synthase in bronchial biospies from patients with aspirin intolerant asthma
47. The potent and selective sulfidopeptide leukotriene antagonist, SK & F 104353, inhibits aspirin-induced asthma
48. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics
49. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma